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Meeting the complex physiological demands of mammalian
life requires strict control of the metabolism of long-chain fatty
acyl-CoAs because of the multiplicity of their cellular functions.
Acyl-CoAs are substrates for energy production; stored within
lipid droplets as triacylglycerol, cholesterol esters, and retinol
esters; esterified to form membrane phospholipids; or used to
activate transcriptional and signaling pathways. Indirect evi-
dence suggests that acyl-CoAs do not wander freely within cells,
but instead, are channeled into specific pathways. In this
review, we will discuss the evidence for acyl-CoA compart-
mentalization, highlight the key modes of acyl-CoA regula-
tion, and diagram potential mechanisms for controlling acyl-
CoA partitioning.
Two prevailing views of metabolic pathways within the cyto-
sol are a) as sequential steps within a largely empty space with
substrates and products traveling from one enzyme to the next,
and b), as embedded within a dense network of proteins and
metabolites, all jockeying for position. In contrast to these two
views, it is likely that synthetic and degradative pathways are
composed of enzymes and their regulators in highly organized
multi-enzyme assemblies designed to enhance efficiency and
regulate steady-state flux (1). Proteins within these assemblies
might interact via their transmembrane and extra-membrane
domains or be tethered to scaffolds, in a manner that is regu-
lated by allosteric effectors and post-translational modifica-
tions (2, 3). Such interactions may be transient, as occurs with
the enzymes that comprise purinosomes (4), or they may be
semi-permanent as occurs within glycogen granules that con-
tain enzymes that synthesize and degrade glycogen, and their
regulatory kinases and phosphatases (5, 6). Assemblies of pro-
teins are advantageous because even without a physical tun-
nel, they can increase reaction rates by enhancing local
substrate concentrations, restricting intermediates from
entering competing reactions, and stabilizing chemically
unstable intermediates.
Because the dysregulation of metabolic homeostasis has been
implicated in a multitude of human diseases, acyl-CoA metab-
olism represents a critical node for understanding whole-body
pathophysiology. Apart from eicosanoid synthesis, the first step
in the metabolism of long-chain fatty acids (FAs)2 is their
thioesterification. The resulting acyl-CoA is then metabo-
lized by one of six major enzyme families: elongases and
desaturases (7), dehydrogenases (8, 9), acyl-CoA thioes-
terases (10, 11), carnitine palmitoyltransferases (CPT) (12),
and lipid and protein acyltransferases (13) (Fig. 1). These
competing pathways, often present within a single subcellu-
lar compartment and coupled with the highly specialized
metabolism of individual cells and tissues, suggest a level of
organization extending beyond enzymatic function. In this
review, we will use a physiological lens to focus on long-
chain mammalian fatty acyl-CoAs and the evidence for com-
partmentalized acyl-CoA metabolism.
Metabolism of Fatty Acids and Acyl-CoAs
Many pathways rely on enzymes that contain membrane-
spanning domains or are tightly associated with membranes.
Plasma membrane, endoplasmic reticulum (ER), and Golgi are
sites of protein acylation (14), and the ER provides the site for
FA -oxidation, for the elongation and desaturation of FAs, for
the synthesis of retinol esters, cholesterol esters, and most
glycerol- and sphingophospholipids, and for the synthesis of
triacylglycerol (TAG). The initial substrate for each of these
pathways is a long-chain acyl-CoA, the product of one of 13
long-chain or very-long-chain acyl-CoA synthetases (ACSL,
ACSVL/FATP, ACS bubblegum (ACSBg)) that activate the FAs
of 14 –26 carbons (15). The metabolism of acyl-CoAs within
cells appears to be highly controlled, and the movement of the
acyl-CoAs themselves seems to be compartmentalized. How
this occurs remains obscure.
Acyl-CoAs are amphipathic molecules with critical micellar
concentrations of 5– 42 M, depending on chain length and
degree of unsaturation (16, 17). However, acyl-CoAs are
unlikely to self-aggregate because, within cells, they are bound
to proteins and membranes. Because the effective free concen-
tration of acyl-CoAs within the cell is estimated to be substan-
tially lower than 200 nM, and because most proteins that have
been found to interact with acyl-CoAs in in vitro experiments
have specific binding affinities in the M range, it has been
suggested that acyl-CoAs may not be effective modulators of
these proteins (18). However, the intracellular concentration of
acyl-CoAs, which is measured as between 5 and 160 M (18), is
probably an inaccurate representation of the concentrations
* This work was supported, in whole or in part, by National Institutes of Health
Grants DK56598 and DK59935 (to R. A. C.) and K08 DK090141 (to E. L. K.).
The authors declare that they have no conflicts of interest with the con-
tents of this article.
1 To whom correspondence should be addressed: 2301 Michael Hooker
Research Center, Dauer Dr., Dept. of Nutrition, University of North Carolina,
Chapel Hill, NC 27599, rcoleman@unc.edu.
2 The abbreviations used are: FA, fatty acid; FATP, FA transport protein; FABP,
FA-binding protein; ACS, acyl-CoA synthetase; ACSL, ACS long-chain;
ACSVL, ACS very-long-chain; ATGL, adipose triglyceride lipase; CPT, carni-
tine palmitoyltransferase; DGAT, diacylglycerol acyltransferase; ER, endo-
plasmic reticulum; GPAT, glycerol-3-phosphate acyltransferase; TAG, tria-
cylglycerol; SREBP, sterol regulatory element-binding protein; PPAR,
peroxisome proliferator-activated receptor; PC, phosphatidylcholine;
ACAT, acyl-CoA acyltransferase.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 290, NO. 33, pp. 20023–20031, August 14, 2015
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
AUGUST 14, 2015 • VOLUME 290 • NUMBER 33 JOURNAL OF BIOLOGICAL CHEMISTRY 20023
MINIREVIEW
within specific membrane domains or near the active sites of
metabolic enzymes.
Is Acyl-CoA Metabolism Compartmentalized?
Several independent lines of data support the hypothesis that
FAs and acyl-CoAs are compartmentalized within cells and
trafficked into specific pathways. Although each is indirect,
taken as a whole, the concept is compelling.
Vectorial Acylation
Exogenous FA uptake into cells is enhanced by vectorial acy-
lation, a process that traps entering FAs by converting them
into acyl-CoAs, which cannot exit the cell (19, 20), and by
downstream metabolic pathways that release the CoA and
allow it to be recycled for additional acyl-CoA synthesis (21).
The cellular locations of the acyl-CoA synthetases are not crit-
ical for FA uptake. Thus, ACSLs and ACSs designated as FA
transport proteins (FATPs) enhance FA uptake even when they
are located on intracellular membranes (22). An example is
provided by similar uptake of arachidonate by each of two dif-
ferentially spliced variants of ACSL4, one located on the plasma
membrane and in the cytosol and the other located on the ER
and lipid droplets (23). Overexpressing ACSL4 at the ER
generated 50% more phosphatidylinositol than when it was
targeted to the mitochondria, compatible with a specific inter-
action with ER enzymes that synthesize or remodel phosphati-
dylinositol. These data provide compelling evidence for com-
partmentalization, as subcellular location of a specific ACSL
isoform may be important for the interaction of FA substrates
with a specific metabolic pathway.
Many downstream proteins that metabolize acyl-CoAs have
a well defined cellular distribution. CPT1, for example, is
expressed on the outer mitochondrial membrane as part of the
machinery to transport activated long-chain acyl-CoAs into the
mitochondrial matrix for -oxidation (24), and the major ester-
ification pathways that use acyl-CoAs are predominantly
located on the ER. However, the location of several putative
intrinsic membrane enzymes may not be static. For example,
incubating Drosophila S2 cells with oleate causes the ER glyc-
erol-3-phosphate acyltransferase (GPAT) to translocate to
newly formed lipid droplets (25), suggesting that GPAT do-
mains formerly believed to constitute transmembrane se-
quences, can instead integrate within the phospholipid mono-
layer that surrounds the lipid droplet. With few exceptions, FA
channeling has not been rigorously evaluated. ACSL1 and
CPT1 interact at the mitochondrial outer membrane, an asso-
ciation that ensures compartmentalized FA channeling into
the mitochondrial matrix (26); the interaction of diacylglyc-
erol acyltransferase (DGAT)-2 and monoacylglycerol acyl-
transferase-2 within a large protein complex via the trans-
membrane domains of DGAT2 should enable cells to
efficiently process acyl-CoAs within the cytosol (27); and
recent co-immunoprecipitation studies have identified pro-
teins in the pathway of TAG synthesis that interact with the
ER protein seipin (28).
FIGURE 1. Metabolic reactions of acyl-CoAs. Long-chain FAs are synthesized de novo from acetate or enter cells from the plasma. They are converted to
acyl-CoAs by ACSL and ACSVL. The reaction is reversed by acyl-CoA thioesterases (ACOT). Acyl-CoAs can be elongated and desaturated, converted to acylcar-
nitines, and metabolized to CO2 via mitochondrial and peroxisomal enzymes, esterified to glycerol-3-phosphate to form lysophosphatidic acid (LPA), phos-
phatidic acid (PA), and TAG, and esterified to monoacylglycerol (MAG) to form diacylglycerol (DAG). Both phosphatidic acid and diacylglycerol are precursors
for all the glycerophospholipids. Acyl-CoAs are also esterified to retinol and cholesterol, acylated to proteins, and incorporated into ceramide to form
sphingolipids. Lipolysis of these products releases fatty acids back into cellular pools. Triacylglycerol, cholesterol esters, and retinol esters are stored in lipid
droplets within cells or secreted from specialized cells as lipoproteins or milk constituents. NEFA, non-esterified fatty acid.
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Evidence from Thermogenesis
FA oxidation in brown adipose is impaired by deficiencies in
several proteins and enzymes that provide a view of what a
multi-protein metabolic cluster might encompass. In addition
to the mitochondrial enzymes of -oxidation, thermogenesis
requires proteins involved in TAG lipolysis and FA transport
and activation (Fig. 2). These proteins include adipose triglyc-
eride lipase (ATGL), a lipid droplet-associated lipase that
releases FAs (29), palmitoyl-protein thioesterase-1, which
diminishes TAG lipolysis (30), FA-binding protein (FABP)-3, a
FA carrier (31, 32), and ACSL1 (33) and FATP1/ACSVL4 (34),
which are FA activators. The block in thermogenesis caused by
the absence of any one of these proteins strongly suggests that
they form an assembly in brown adipose that metabolizes a pool
of FAs that originate in lipid droplets and are specifically tar-
geted to CPT1 for -oxidation. In addition, the thioesterase,
Them2, and its binding partner phosphatidylcholine transfer
protein, enhance thermogenesis, suggesting that these, too, are
members of the thermogenic cluster (35).
Metabolism of de Novo Synthesized FA
Studies of mice deficient in acyl-CoA synthetases suggest
that acyl-CoAs may be sequentially synthesized, hydrolyzed,
and resynthesized, perhaps as they are targeted to different
organelles within cells. For example, we can construct a se-
quence beginning with the insulin-induced de novo synthesis of
16:0 within the cytosol, followed by conversion to 16:0-CoA by
an ACSL and then esterification to form lysophosphatidic acid
by GPAT1, which is embedded in the outer mitochondrial
membrane and prefers saturated FAs that have been synthe-
sized de novo (36). In GPAT1-deficient mice, FA oxidation
increases, suggesting that GPAT1 and CPT1 compete at the
mitochondrial membrane for a specific pool of acyl-CoAs (37).
Regulation occurs via SREBP1- and carbohydrate-responsive
element-binding protein (ChREBP)-mediated up-regulation of
enzymes of FA synthesis and GPAT1 (13), so that when acyl-
CoAs are the product of de novo biosynthesis, their capture by
GPAT1 prevents newly synthesized FAs from subsequent
-oxidation.
In contrast to this evidence for intracellular FA compart-
mentalization, dietary triolein supplementation restores lipid
accumulation in stearoyl-CoA desaturase 1 (SCD1)-deficient
liver (38). However, because dietary triolein does not correct
the phenotype in global SCD1 deficiency, exogenous and
endogenous oleate pools may be metabolized differently in
extrahepatic tissues.
ACSL1 Knock-out Mice
Studies of ACSL1 knock-out mice provide the most persua-
sive argument for compartmentalized acyl-CoA metabolism. In
liver, ACSL1 is equally distributed on the ER and the mitochon-
drial outer membrane. Because it comprises only 50% of the
total ACS activity in either location, its absence results in minor
decreases in TAG synthesis and FA oxidation (39). In contrast,
in highly oxidative tissues, including heart, skeletal muscle, and
brown adipose, ACSL1 constitutes 90% of total ACS activity
and its absence severely diminishes FA oxidation, although the
remaining ACSL isoforms are sufficient for normal TAG and
membrane phospholipid biosynthesis (33, 40, 41). One might
reason that when ACSL1 is absent, FA oxidation would be neg-
FIGURE 2. A hypothetical assembly of proteins, substrates, and products that are critical for thermogenesis in brown adipocytes. Mice are unable to
maintain a normal body temperature if they lack ATGL, FABP3, FATP1, and ACSL1 or are heterozygotes for CPT1. 1) ATGL hydrolyzes FA from TAG in lipid
droplets. 2) FABP3 binds these released FAs and transports them to FATP1 and ACSL1, which convert them to acyl-CoAs (A-CoA). 3) These acyl-CoAs are
substrates for CPT1, which converts them to acylcarnitines (AC) that enter the mitochondrial matrix and are metabolized by -oxidation to produce heat. 4)
Thioesterase superfamily member-2 (Them2) and its partner phosphatidylcholine transfer protein (PC-TP) improve the thermogenic process by converting
acyl-CoAs, perhaps those formed in other locations, back to fatty acids that can be reactivated by FATP1 and ACSL1 located at the mitochondrial membrane.
TCA, tricarboxylic acid cycle.
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ligible, merely because less exogenous FA enters the cells. Argu-
ing against this interpretation, however, are data from mice
deficient in skeletal muscle ACSL1 (41). Because FAs cannot be
used for fuel, these mice can run only half as far as their wild
type littermates before becoming hypoglycemic. Surprisingly
however, their muscle content of long-chain acyl-CoA in-
creases 10-fold during exercise and at exhaustion is 89% higher
than controls. The low muscle content of long-chain acylcar-
nitines confirms that the large amount of acyl-CoA synthesized
by other ACSL isoforms in ACSL1-deficient muscle is metabol-
ically unavailable for -oxidation.
Similar to skeletal muscle, ACSL1 is the predominant ACS in
heart. Genetic deletion of ACSL1 results in a 97% decrease in
total long-chain acyl-CoAs (40). This decrease results in a
nearly complete inhibition of mitochondrial FA oxidation,
although membrane phospholipid and TAG synthesis remain
intact. Again, it appears that mitochondrial ACSL1 is essential
in the heart to partition FA toward oxidation. ACSL1 functions
similarly in adipose tissue (33). When mice are challenged with
cold exposure, brown adipose FAs cannot be mobilized from
the TAG stored in lipid droplets and are unavailable for mito-
chondrial oxidation and thermogenesis, and even in white adi-
pose, the reduced -oxidation results in preferential partition-
ing of FA into TAG stores (33).
ACSL Subcellular Location
Intracellular FAs originate from three primary sources, exog-
enous FAs that enter cells from the blood or from the gut
lumen, FAs that arise via de novo synthesis from acetate, and
FAs that are released within the cell by the hydrolysis of acy-
lated proteins, phospholipids, and TAG. Indirect data suggest
that FAs originating from each source comprise distinct intra-
cellular pools and are preferentially activated by specific acyl-
CoA synthetases and directed into specific metabolic pathways.
For example, FAs derived from de novo synthesis versus exoge-
nous sources are metabolized differently by GPAT isoforms
located on the mitochondria or the ER (36) and even by the two
DGAT isoforms, located on the ER or on lipid droplets (42– 44).
Although subcellular location ought to critically define
aspects of acyl-CoA partitioning, studies of the ACSL isoforms
have been problematic. Subcellular fractionation frequently
results in contamination of specific organelles with other cellu-
lar constituents. For example, several ACSL isoforms have been
identified by proteomic studies of lipid droplets, but it remains
unclear as to whether discrepancies in these reports reflect sta-
ble or transient associations of a particular ACSL on the lipid
droplet or, instead, contamination with fragments of associated
ER (45). Confocal studies are superior in that the normal cell
structure is not disrupted, but they depend on highly specific
antibodies to native proteins, and may not identify proteins
expressed at low amounts in some organelles. Overexpression
studies, particularly with tagged proteins, may not reflect the
endogenous location or interactions with other proteins. The
reported interaction of FATP1 and ACSL1 (46), for example,
should be re-examined using a confocal method. Massively
overexpressing a protein may result in ER retention and may
not mirror the location of the native protein.
In addition to technical limitations in assigning location, the
individual ACSL isoforms appear to move in response to
changes in physiologic stimuli. Similar to studies of GPAT4
(25), treatment with exogenous FA causes tagged ACSL3 to
move from the ER to newly forming lipid droplets (47), and a
knockdown of Acsl3 in hepatocytes reduces de novo FA synthe-
sis (48, 49), suggesting that ACSL3 is involved in the flux of
acyl-CoAs toward storage. Treatment with insulin stimulates
FATP1 translocation from the ER to the plasma membrane and
increases the intracellular content of long-chain FA.
In addition to physiologic changes, the location of ACSL iso-
forms may be tissue-dependent, but few studies have reported
on both location and function. Thus, the presence of ACSL5 on
liver mitochondria (50) suggested that, like ACSL1, ACSL5
would target FA toward -oxidation. However, although over-
expressed ACSL5 in McArdle-RH7777 cells was located on
both mitochondria and ER, oleate incorporation increased only
into TAG and not into oxidation products (51). In support of
these data, the siRNA knockdown of ACSL5 in rat primary
hepatocytes decreased oleate-mediated TAG synthesis and
lipid droplet formation (52).
Nutritional Regulation
To maintain energy homeostasis, cells must adapt rapidly to
the available nutrients. Switching between glucose and FAs (53)
is regulated by the cellular level of malonyl-CoA, which inhibits
CPT-I, thereby blocking the mitochondrial entry and oxidation
of long-chain fatty acyl-CoAs, which are then available for
esterification into glycerolipids. During fasting, rising cellular
AMP levels activate AMP-activated protein kinase, which
enhances ATP-generating pathways that diminish malonyl-
CoA production, thereby relieving the inhibition of CPT-I. In
addition, fasting induces TAG lipolysis, and the released FAs
activate the deacetylase, SIRT1, and the PPAR co-activator,
PGC1, to increase mitochondrial biogenesis (54). Thus, cyto-
solic metabolites control the metabolic fate of the acyl-CoAs.
Nutrient status similarly controls the transcription of ACSL
isoforms. In rat liver, fasting increases and refeeding decreases
the mRNA abundance of Acsl1 and Acsl4, whereas the expres-
sion of Acsl5 mRNA responds in the opposite manner (55).
However, even these changes can be altered by dietary nutri-
ents, so that fasted rats that are refed with a high-fat (20% soy-
bean oil) diet increase Acsl1 mRNA expression in liver (56).
Transcriptional regulation of ACSL isoform mRNA expres-
sion depends on activated PPARs. In heart, liver, and skeletal
muscle, PPAR activation increases the transcription of Acsl1
(57, 58), but in adipocytes, the transcription of Acsl1 is
enhanced by PPAR (59), Acsl4 transcription in liver is also
increased by PPAR/ activation (60). Although synthetic
ligands were used to activate the PPAR isoforms, these studies
suggest that, as PPAR ligands, endogenous and exogenous FAs
or acyl-CoAs may themselves alter ACSL isoform expression
and activity.
Although in vitro experiments must be interpreted cau-
tiously, FAs appear to control ACSL expression, perhaps via
PPAR activation. Exogenous oleate added to rat cardiomyo-
cytes increases Acsl1 expression (57), and in rat insulinoma
cells or mouse hepatocytes, polyunsaturated FAs, but not satu-
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rated or monounsaturated FAs, reduce both Acsl4 mRNA and
protein expression (61, 62). Polyunsaturated FAs also increase
ACSL4 protein degradation via a ubiquitination-dependent,
proteasomal degradative pathway (62). In addition to promot-
ing changes in subcellular location, insulin increases Acsl1 and
Acsl5 expression in cultured hepatoma cells (63), Acsl1 and
Acsl3 expression in rat cardiomyocytes, and Acsl6 expression in
cardiomyocytes (57). It is not known whether the inductive
effect of insulin on the ACSL isoforms is mediated by SREBP.
These insulin exposure studies appear to be at odds with fasting
studies in which one would expect that insulin levels would be
relatively low.
Polyunsaturated FAs are natural ligands for nuclear tran-
scription factors such as the PPARs, liver X receptors (LXRs),
HNF-4, and SREBPs 1 and 2, but their chain length, degrees of
unsaturation, and source (exogenous versus de novo) have dif-
ferential effects on the gene regulation. For example, hepatic
PPAR binds oleate, arachidonate, and docosahexaenoic acid
with near equal affinity (64); however, in rat hepatocytes, only
docosahexaenoic acid activates PPAR (65). These observa-
tions suggest that the metabolism of specific FA species is
highly organized, supporting the hypothesis that acyl-CoAs are
compartmentalized.
ACSL Substrate Preference
The Yamamoto group (66), which cloned the five rat ACSL
isoforms, used a coupled spectrophotometric assay to identify
the FA preferences of purified recombinant rat isoforms.
Although all isoforms activated saturated and unsaturated FAs
of 16 –20 carbons, ACSL6 (originally called ACSL2) had higher
activities with 20:46, 20:53, and 22:63, suggesting that it
might be involved in the metabolism of brain phospholipids,
which have a high content of polyunsaturated FAs, or in eico-
sanoid function (67, 68). In fact, in differentiating PC12 cells,
ACSL6 enhances both the uptake of 22:6 and neurite outgrowth
(69, 70). ACSL4 has a reported preference for arachidonate, and
as might be expected, the incorporation and the secretion of
eicosanoids and arachidonate are diminished when ACSL4 is
knocked down in INS832/13 (61), 3Y1 rat fibroblast (71), and
activated hepatic stellate cells (HSC) (72). However, the pub-
lished substrate preference for each ACSL family member is not
invariably observed. For example, although the purified recom-
binant ACSL1 had no preference for arachidonate or linoleate,
ACSL1 is critical for the synthesis of arachidonoyl-CoA in
macrophages (73) and was inferred to prefer linoleate in the
heart (74). Studies performed in different cell lines also reveal
disparate effects of ACSL4 deficiency on arachidonic acid
metabolism for phospholipid synthesis and prostaglandin
secretion. In 3Y1 and HSC cells, siRNA-mediated knockdown
of ACSL4 reduces the incorporation of arachidonic acid into
phosphatidylcholine and dramatically decreases the secretion
of prostaglandins, but in INS cells, the deficiency of ACSL4 has
no effect on the incorporation of arachidonic acid into PC.
Instead, the knockdown of ACSL4 in INS cells results in
increased unesterified epoxyeicosatrienoic acids because of
diminished activation and esterification into glycerolipids.
Most members of the closely related FATP family (also called
ACSVL for ACS very-long-chain) can use FAs of 16 –24 car-
bons (75). Because each tissue expresses several ACSL and
FATP/ACSVL isoforms, the location of the isoform might
direct a particular chain length FA into a specific pathway.
Although not experimentally demonstrated, products synthe-
sized by the same acyltransferase, but that differ in FA compo-
sition, suggest that a specific ACSL isoform must provide the
esterifying enzyme with larger amounts of specific acyl-CoA
substrates. Such products include the overwhelming predomi-
nance of cholesteryl oleate in liver and LDL (76) and the pre-
dominance of cholesteryl adrenate (22:46) and cholesteryl
arachidonate (20:4 6) in rat adrenal cortex (77). Because the
substrate preference of ACAT1, which is present in rat adrenal
cortex (76), is oleate, whereas ACAT2 esterifies 18:1, 20:5, and
22:5 equally (78), the composition of tissue cholesteryl esters
seems more aligned with the ACSL isoforms than the ACAT
isoforms present in each tissue. Similarly, 77% of cardiolipin
species in heart and skeletal muscle, in which ACSL1 contrib-
utes more than 90% of total ACSL activity, are tetra-18:2 (79),
whereas tetralinoleoyl-cardiolipin is 50% of the cardiolipin
species in liver (69), a tissue in which ACSL1 is responsible for
only about 50% of the total ACSL activity (39). In brain, where
ACSL1 is minimally expressed (55), the major cardiolipin acyl
chains are oleate and arachidonate (80).
PC biosynthesis has also been linked to ACSL3 activity; in
human hepatoma Huh7 cells, siRNA-mediated knockdown of
Acsl3 diminishes oleate incorporation into PC and reduces
VLDL secretion (81). Thus, ACSL3 may activate FAs destined
for the synthesis of the phosphatidylcholine that is essential for
VLDL secretion (81). Taken together, these findings demon-
strate that, depending upon cell type, different ACSL isoforms
activate specific FAs that can be incorporated into a variety of
glycerolipids. Furthermore, although each ACSL isoform may
have a specific substrate preference, the function of each ACSL
isoform seems to vary in different cell types.
ACSL Isoforms and Signaling Acyl-CoAs
Lipolysis-derived FAs and acyl-CoAs have been implicated
as essential intracellular signaling metabolites (82). As signaling
molecules, acyl-CoAs link the nutritional environment to tran-
scription factors capable of reorganizing cellular metabolism to
ensure an adequate response to changes in nutrient availability
and to maximize metabolic efficiency (83). For example, ACSL3
appears to promote de novo lipogenesis and storage of neutral
lipid because the siRNA knockdown of Acsl3 in primary rat
hepatocytes also diminishes the expression of PPAR, carbohy-
drate-responsive element-binding protein, SREBP1c, and liver
X receptor  as well as the expression of the target genes of
these transcription factors (48).
Specific pools of FAs or acyl-CoAs are critical in the heart. In
hearts deficient in ATGL, the impaired release of FAs from
stored TAG results in low expression of PPAR target genes,
inadequate FA oxidation, TAG accumulation, and heart failure
(84 – 87). Because treating mice with fibrates increased FA oxi-
dation, reduced TAG stores, and improved heart function, it
appeared that the ATGL deficiency had reduced the availability
of FAs and/or acyl-CoA ligands required to activate PPAR;
thus, despite high levels of acyl-CoAs that partitioned into neu-
tral lipids, exogenously derived FAs were not PPAR ligands
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(86). A competing interpretation suggests that the effect of
ATGL-derived FAs on PPAR is mediated indirectly by SIRT1
(54), but the data from both studies are consistent with tran-
scriptional signaling by distinct pools of FA and acyl-CoAs
originating from a specific endogenous source.
Mechanisms, Possibilities, and Unanswered Questions
The wide range of functions initiated by each ACSL isoform
suggests three major problems. First, the different effects
observed in cell lines of similar origin suggest that analyzing
function in the relevant primary cells would provide the most
reliable and conclusive information. Second, in addition to mis-
localizing proteins, overexpression studies can overwhelm
downstream metabolic pathways, resulting in a misleading
interpretation of function (88). For example, when ACSL1 is
overexpressed in primary hepatocytes, the protein localizes to
the ER and increases oleate re-esterification into diacylglycerol
and phospholipids (89). In contrast, the liver-specific knock-
out of ACSL1 disrupts TAG synthesis and oxidation only mildly
(39, 89). Thirdly, the disparate physiological effects observed in
different tissues when ACSL1 is absent suggest that protein-
protein interactions between ACSL isoforms and downstream
metabolic enzymes vary considerably in tissues that have spe-
cialized physiological functions. Thus, differing strongly from
the FA storage and degradation pathways affected in ACSL1-
deficient liver, adipose, skeletal muscle, or heart, ACSL1 in
macrophages predominantly mediates inflammatory effects
and channels FAs toward the synthesis of phospholipid (90, 91),
whereas ACSL1 in endothelial cells is unrelated to inflamma-
tory changes associated with dietary fat (92). Clearly, a better
understanding of the locations of each of the ACSLs and their
downstream partners is needed.
Important questions remain concerning the trafficking of
FAs and acyl-CoAs. We do not know how exogenous FAs are
transported from the cytosolic face of the plasma membrane to
ACSL isoforms that are located on intracellular membranes.
Interaction with the intracellular acyl-CoA-binding proteins or
FABP might direct FAs and acyl-CoAs to specific sites within
cells. Although directional transport by these binding proteins
has been inferred, it has not been demonstrated (93). For exam-
ple, the absence of FABP4 diminishes PPAR activation by FA
(94), and FABP4 enhances lipase activity by interacting with
hormone-sensitive lipase (HSL) to bind released FAs (95).
Although the absence of FABP and acyl-CoA-binding proteins
alters lipid metabolism, the function of these carrier proteins
may be more analogous to that of albumin in allowing FAs and
acyl-CoAs to be used by enzymes or to bind to transcription
factors in a controlled manner (96).
Although indirect data imply the existence of organized
assemblies of enzymes that metabolize acyl-CoAs, definitive
proof is absent. Newer methods, both physical and in silico,
must be sought to identify protein partners and interactions
without the potential hazards of overexpression (97–99). We
also lack any understanding of why the up-regulation of -oxi-
dation not only increases the expression of Acsl1, but, counter-
productively, also increases the expression of thioesterases
such as Them2 and its partners (35). It is unclear as to how
protein assemblies form in response to specific nutrient or
energy signals. If proteins associate with each other or with
scaffolding proteins through the interactions of specific
domains, what then causes them to disperse? Phosphorylation
and acetylation of ACSL1 are modified hormonally on numer-
ous sites (100), but the functions of these post-translational
modifications are unknown. The answers to these questions
demand new tools to identify the movements of lipids within
cells and new methods to capture transient protein assemblies
and to manipulate them.
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